![]() Cardiac dimensions and function were retrieved, including data from echocardiography and cardiac magnetic resonance imaging, if available. ![]() The data that support the findings of this study are available from the corresponding author upon reasonable request.Īll available demographics, baseline, and pre-, peri- and post-procedural data (<7 days from the time of the procedure) were collected from patient medical records. This study was performed in accordance with the Declaration of Helsinki. The study was approved by the ethical boards of each contributing center, and informed consent was retrieved at each center in accordance with local and national regulations. The earliest patient enrolled had his atrial procedure performed in 2014, while the last patient enrolled had her procedure performed in 2020. George, Hamburg, Germany Fuwai University Hospital, Beijing, China Aarhus Hospital, Denmark Skane University Hospital, Sweden Linkoeping University Hospital, Sweden Azienda Ospedaliera Luigi Sacco, Italy University Clinic Hamburg-Eppendorf, Germany University Hospital of Ancona, Italy Heart Center University of Leipzig, Germany) were retrospectively searched for all consecutive ARVC patients fulfilling the inclusion criteria of the study. The ARVC registries at 12 tertiary care institutions (University Hospital Zurich, Switzerland Johns Hopkins Medical University, USA IRCCS Centro Cardiologico Monzino, Italy Asklepios Clinic St. Therefore, the aim of this international multicenter study was to analyze the efficacy and safety of CA for the treatment of atrial arrhythmias in patients with ARVC. Data regarding the use, safety, and efficacy of CA in the management of atrial arrhythmias in ARVC are scarce, and previous work is limited to a few small sample-sized reports. Ĭatheter ablation (CA) is an effective therapy for the treatment of atrial arrhythmias in the general population. Particularly, atrial fibrillation (AF) and atrial flutter (AFl) were shown to be more frequent and presented at a younger age in patients with ARVC as compared to the general population. first described an altered electrical conduction within the atria of patients with ARVC, and subsequent cohort studies reported a high rate of atrial arrhythmias in ARVC. Considering electrocardiographic features, Platonov PG et al. The atria of patients with ARVC have been shown to be dilated and their function impaired, with the right atrium (RA) being predominantly affected by this process. Although ventricular dysfunction and ventricular arrhythmias represent the hallmarks of ARVC, a growing body of evidence from both ARVC animal models and patient cohorts has indicated atrial involvement. Conclusions: CA is safe and effective in managing atrial arrhythmias in patients with ARVC, with success rates comparable to the general population.Īrrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiomyopathy characterized by a progressive myocardial fibro-fatty infiltration (FFI), predominantly originating in the right ventricle (RV). One major complication (2.7% PV stenosis requiring PV stenting) occurred. All patients undergoing CTI ablation were free from atrial arrhythmia recurrences at 6 months, with 89% single-procedural arrhythmic freedom at last follow-up. After focal AT ablation, freedom from atrial arrhythmia recurrence was 80%, 80%, and 60% at 6 months, 12 months, and last follow-up, respectively. The median follow-up period was 27 (13–67) months, and 96%, 74%, and 61% of patients undergoing AF ablation were free from any atrial arrhythmia recurrence after a single procedure at 6 months, 12 months, and last follow-up, respectively. Acute procedural success was achieved in all procedures but one ( n = 1 focal left AT 97% acute success). The arrhythmia leading to CA was AF in 23 (62%), focal left AT in 5 (14%), and CTI-dependent AFl in 9 (24%). Results: Thirty-seven patients were enrolled in the study (age 50.2 ± 16.6 years, male 84%, CHA 2DS 2VASc 1 (1,2), HAS-BLED 0 (0–2)). Demographic, periprocedural, and long-term arrhythmic outcome data were collected. Methods: In this international collaborative effort, all patients with a definite diagnosis of ARVC undergoing CA for atrial fibrillation (AF), focal atrial tachycardia (AT), or cavotricuspid isthmus (CTI)-dependent atrial flutter (AFl) were extracted from twelve ARVC registries. Objective: To assess the safety and efficacy of CA for atrial arrhythmias in patients with ARVC. ![]() Data regarding CA for atrial arrhythmias in ARVC are scarce. Catheter ablation (CA) is an effective treatment for atrial arrhythmias in the general population. Background: Atrial arrhythmias are present in up to 20% of patients with arrhythmogenic right ventricular cardiomyopathy (ARVC).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |